Healthcare - Biotechnology - NASDAQ - US
$ 3.22
-2.72 %
$ 272 M
Market Cap
-1.56
P/E
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection.[ Read More ]
The intrinsic value of one AVIR stock under the base case scenario is HIDDEN Compared to the current market price of 3.22 USD, Atea Pharmaceuticals, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart AVIR
FINANCIALS
0
REVENUE
-164 M
OPERATING INCOME
-136 M
NET INCOME
-85.4 M
OPERATING CASH FLOW
40.3 M
INVESTING CASH FLOW
257 K
FINANCING CASH FLOW
0
REVENUE
-37.2 M
OPERATING INCOME
-31.2 M
NET INCOME
-23 M
OPERATING CASH FLOW
-122 M
INVESTING CASH FLOW
117 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Atea Pharmaceuticals, Inc.
| Current Assets | 590 M |
| Cash & Short-Term Investments | 578 M |
| Receivables | 0 |
| Other Current Assets | 12.3 M |
| Non-Current Assets | 4.51 M |
| Long-Term Investments | 0 |
| PP&E | 3.12 M |
| Other Non-Current Assets | 1.4 M |
| Current Liabilities | 32.4 M |
| Accounts Payable | 4.25 M |
| Short-Term Debt | 760 K |
| Other Current Liabilities | 27.4 M |
| Non-Current Liabilities | 7.4 M |
| Long-Term Debt | 1.64 M |
| Other Non-Current Liabilities | 5.76 M |
EFFICIENCY
Earnings Waterfall
Atea Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 70.1 M |
| Gross Profit | -70.1 M |
| Operating Expenses | 94.1 M |
| Operating Income | -164 M |
| Other Expenses | -28.2 M |
| Net Income | -136 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-24.49%
ROE
-22.85%
ROA
-29.79%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Atea Pharmaceuticals, Inc.
| Net Income | -136 M |
| Depreciation & Amortization | 416 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 49.4 M |
| Change in Working Capital | 16.2 M |
| Others | 47.6 M |
| Free Cash Flow | -85.4 M |
Wall Street Analysts Price Targets
Atea Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for AVIR of $6.88 , with forecasts ranging from a low of $6.88 to a high of $6.88 .
AVIR Lowest Price Target
Wall Street Target
6.88 USD
113.66%
AVIR Average Price Target
Wall Street Target
6.88 USD
113.66%
AVIR Highest Price Target
Wall Street Target
6.88 USD
113.66%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Atea Pharmaceuticals, Inc.
Sold
0-3 MONTHS
234 K USD 1
3-6 MONTHS
65.2 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
488 K USD 6
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 months ago
Sep 17, 2024
|
Sell 137 K USD
|
Sommadossi Jean-Pierre
President, CEO, and Chairman |
- 33941
|
4.0458 USD |
|
1 month ago
Sep 18, 2024
|
Sell 89.5 K USD
|
Sommadossi Jean-Pierre
President, CEO, and Chairman |
- 22187
|
4.0325 USD |
|
1 month ago
Sep 19, 2024
|
Sell 7.37 K USD
|
Sommadossi Jean-Pierre
President, CEO, and Chairman |
- 1841
|
4.0019 USD |
|
4 months ago
Jun 20, 2024
|
Sell 61.1 K USD
|
Polsky Bruce
Director |
- 17544
|
3.4852 USD |
|
5 months ago
Jun 05, 2024
|
Sell 4.02 K USD
|
Sommadossi Jean-Pierre
President, CEO, and Chairman |
- 1006
|
4 USD |
|
9 months ago
Feb 01, 2024
|
Sell 60.9 K USD
|
Corcoran Andrea
See Remarks |
- 15843
|
3.8449 USD |
|
9 months ago
Feb 01, 2024
|
Sell 219 K USD
|
Sommadossi Jean-Pierre
President, CEO, and Chairman |
- 56910
|
3.845 USD |
|
9 months ago
Feb 01, 2024
|
Sell 61 K USD
|
Horga Maria Arantxa
Chief Medical Officer |
- 15870
|
3.8414 USD |
|
9 months ago
Feb 01, 2024
|
Sell 47.9 K USD
|
Foster Wayne
EVP, Chief Accounting Officer |
- 12477
|
3.8394 USD |
|
9 months ago
Feb 01, 2024
|
Sell 45.4 K USD
|
Vavricka John
Chief Commercial Officer |
- 11819
|
3.843 USD |
|
9 months ago
Feb 01, 2024
|
Sell 53.9 K USD
|
Hammond Janet MJ
Chief Development Officer |
- 14029
|
3.843 USD |
|
2 years ago
Nov 11, 2022
|
Sell 131 K USD
|
BERGER FRANKLIN M
Director |
- 25500
|
5.1503 USD |
|
2 years ago
Nov 14, 2022
|
Sell 83.4 K USD
|
BERGER FRANKLIN M
Director |
- 16166
|
5.156 USD |
|
2 years ago
Dec 20, 2021
|
Bought 103 K USD
|
Murphy Polly A.
Director |
+ 12000
|
8.5663 USD |
|
4 years ago
Nov 03, 2020
|
Bought 5.82 M USD
|
Rock Springs Capital Management LP
10 percent owner |
+ 242708
|
24 USD |
|
4 years ago
Nov 03, 2020
|
Bought 175 K USD
|
Rock Springs Capital Management LP
10 percent owner |
+ 7292
|
24 USD |
|
4 years ago
Nov 03, 2020
|
Bought 6 M USD
|
Hack Andrew A. F.
Director |
+ 250000
|
24 USD |
|
4 years ago
Nov 03, 2020
|
Bought 1 M USD
|
BERGER FRANKLIN M
Director |
+ 41666
|
24 USD |
7. News
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for the treatment of HCV. These data are being presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA.
globenewswire.com
- 2 days ago
Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Jonae Barnes - SVP of Investor Relations and Corporate Communications Dr. Jean-Pierre Sommadossi - Founder, Chairman and Chief Executive Officer Dr. Janet Hammond - Chief Development Officer John Vavricka - Chief Commercial Officer Dr. Arantxa Horga - Chief Medical Officer Andrea Corcoran - Chief Financial Officer and Executive Vice President of Legal Conference Call Participants Isabella Camaj - JPMorgan Andy Hsieh - William Blair Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
seekingalpha.com
- 1 week ago
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4'24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases' (AASLD's) The Liver Meeting 2024 Pharmacokinetic Data for Bemnifosbuvir to be Presented at American College of Pharmacometrics Meeting Conference Call at 4:30 pm ET Today BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a business update. “We continue to make significant progress in our HCV program with the combination of bemnifosbuvir and ruzasvir, which has a potential best-in-class profile.
globenewswire.com
- 1 week ago
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced three upcoming poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for Hepatitis C Virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for HCV. These data will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA.
globenewswire.com
- 2 weeks ago
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Doximity (DOCS) have performed compared to their sector so far this year.
zacks.com
- 1 month ago
New Strong Buy Stocks for October 16th
CLPR, REE, HMY, AVIR and WPRT have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2024.
zacks.com
- 1 month ago
Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Atea Pharmaceuticals (AVIR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
- 1 month ago
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and PetIQ (PETQ) have performed compared to their sector so far this year.
zacks.com
- 1 month ago
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for the treatment of COVID-19. The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with mild to moderate COVID-19. In SUNRISE-3, bemnifosbuvir was generally safe and well tolerated.
globenewswire.com
- 2 months ago
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and McKesson (MCK) have performed compared to their sector so far this year.
zacks.com
- 2 months ago
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway
New Data Further Elucidates Bemnifosbuvir's Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RNA Viruses New Data Further Elucidates Bemnifosbuvir's Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RNA Viruses
globenewswire.com
- 2 months ago
All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy
Atea Pharmaceuticals (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 3 months ago
8. Profile Summary
Atea Pharmaceuticals, Inc. AVIR
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 272 M
Dividend Yield
0.00%
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Contact
125 Summer Street, Boston, MA, 02110
https://ateapharma.com
IPO Date
Oct. 30, 2020
Employees
75
Officers
Ms. Jonae R. Barnes
Senior Vice President of Investor Relations & Corporate Communications
Mr. Ariyapadi N. Krishnaraj
Vice President of Marketing
Mr. Wayne Foster CPA
Executive Vice President of Finance & Chief Accounting Officer
Dr. Janet M. J. Hammond M.D., Ph.D.
Chief Development Officer
Mr. Adel Moussa Ph.D.
Executive Vice President of Chemistry
Mr. Xiao-Jian Zhou Ph.D.
Executive Vice President of Early Stage Development
Dr. Maria Arantxa Horga M.D.
Chief Medical Officer
Mr. John F. Vavricka
Chief Commercial Officer
Dr. Jean-Pierre Sommadossi Ph.D.
Founder, Chairman, Chief Executive Officer & President
Ms. Andrea J. Corcoran J.D.
Chief Financial Officer, Executive Vice President of Legal & Secretary